For administration to dogs.

Administer orally, once daily, with food. In clinical studies, an average starting dose of 6 mg/kg once daily was effective. The dose should then be titrated according to individual response as determined by monitoring (see below). Practical starting doses are recommended as follows:

In clinical studies, most dogs were eventually stabilised on doses between 2-10 mg/kg/day.

Should symptoms not be adequately controlled for an entire 24 hour inter-dose period, consideration should be given to increasing the daily dose by as small an increment as possible and dividing it between morning and evening doses. Do not divide or open capsules. A small number of animals may require doses significantly in excess of 10 mg per kg bodyweight per day. In these situations appropriate additional monitoring should be implemented.

Due to the limitation in capsule size, it may not be possible to provide optimal control for smaller dogs.

Monitoring: Samples should be taken for biochemistry (including electrolytes) and an ACTH stimulation test pre-treatment and then at 10 days, 4 weeks, 12 weeks, and thereafter every 3 months, following initial diagnosis and after each dose adjustment. It is imperative that ACTH stimulation tests are performed 4-6 hours post-dosing to enable accurate interpretation of results.

Regular assessment of the clinical progress of the disease should also be made at each of the above time points.

Dogs should be monitored at regular intervals for primary hepatic disease, renal disease, and for diabetes mellitus.

Do not use in dogs weighing less than 20 kg.

Only complete blister strips should be dispensed.